Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 14, 2012

 

 

ALIMERA SCIENCES, INC.

(Exact name of Registrant as specified in its charter)

 

 

 

Delaware   001-34703   20-0028718

(State or other Jurisdiction

of Incorporation)

 

(Commission

File No.)

 

(IRS Employer

Identification No.)

     

6120 Windward Parkway

Suite 290

Alpharetta, Georgia

  30005
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (678) 990-5740

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 5.07. Submission of Matters to a Vote of Security Holders.

At the 2012 annual meeting of stockholders of Alimera Sciences, Inc. (the “Company”) held on June 14, 2012 (the “Annual Meeting”), the following proposals were submitted to the stockholders of the Company:

 

Proposal 1:    The election of two directors to serve as Class II directors for a term of three years until the 2015 annual meeting of stockholders.
Proposal 2:    The ratification of the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2012.
Proposal 3:    The approval on an advisory, non-binding basis of the compensation of the Company’s named executive officers.

For more information about the foregoing proposals, see the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 30, 2012 (the “Proxy Statement”). Of the 31,427,445 shares of the Company’s common stock entitled to vote at the Annual Meeting, 25,083,583 shares, or approximately 79.8%, were represented at the meeting in person or by proxy, constituting a quorum. The number of votes cast for, against or withheld, as well as abstentions and broker non-votes, if applicable, in respect of each such matter is set forth below:

 

Proposal 1: Election of Directors.

The Company’s stockholders elected the following two directors to serve as Class II directors until the 2015 annual meeting of stockholders. The votes regarding the election of directors were as follows:

 

Director

   Votes For      Votes Withheld      Broker Non-Votes  

Philip R. Tracy

     17,913,947         29,231         7,140,405   

Glen Bradley, Ph.D.

     17,914,037         29,141         7,140,405   

 

Proposal 2: Ratification of Selection of Deloitte & Touche LLP.

The Company’s stockholders ratified the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2012. The votes regarding this proposal were as follows:

 

Votes For

 

Votes Against

 

Votes Abstaining

 

Broker Non-Votes

24,948,435

  32,273   102,875   0

 

Proposal 3: Compensation of Officers.

The Company’s stockholders approved on an advisory, non-binding basis the compensation paid to the Company’s named executive officers, as disclosed in the Proxy Statement. The votes regarding this proposal were as follows:

 

Votes For

 

Votes Against

 

Votes Abstaining

 

Broker Non-Votes

17,856,604

  57,817   28,757   7,140,405


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

ALIMERA SCIENCES, INC.

By:

 

/s/ RICHARD S. EISWIRTH, JR.

  Name: Richard S. Eiswirth, Jr.
  Title: Chief Operating Officer and Chief Financial Officer

Dated: June 15, 2012